Paper42426348
Reversible and irreversible BTK inhibition promotes stem-like functional multipotency, persistence, and antitumor efficacy of CD19-directed CAR T cells in mantle cell lymphoma.
Yao Y and 6 others. Leukemia, 2026. Cited by 0 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Reversible and irreversible BTK inhibition promotes stem-like functional multipotency, persistence, and antitumor efficacy of CD19-directed CAR T cells in mantle cell lymphoma. Papers, record 42426348. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42426348
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Reversible and irreversible BTK inhibition promotes stem-like functional multipotency, persistence, and antitumor efficacy of CD19-directed CAR T cells in mantle cell lymphoma.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| AWD00008424 | Janssen Research and Development (Janssen R&D) | PubMed |
Source PubMed
References14
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33932067 | Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma. | Cancer Sci | 2021 | https://conductscience.org/library/papers/33932067 | PubMed |
| 2 | 37883795 | CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study. | Blood | 2024 | https://conductscience.org/library/papers/37883795 | PubMed |
| 3 | 33230330 | MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects. | Nat Immunol | 2021 | https://conductscience.org/library/papers/33230330 | PubMed |
| 4 | 35596920 | BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner. | Curr Oncol Rep | 2022 | https://conductscience.org/library/papers/35596920 | PubMed |
| 5 | 35561314 | Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma. | Blood Adv | 2022 | https://conductscience.org/library/papers/35561314 | PubMed |
| 6 | 36086817 | Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies. | Mol Ther | 2023 | https://conductscience.org/library/papers/36086817 | PubMed |
| 7 | 39779871 | A multi-kinase inhibitor screen identifies inhibitors preserving stem-cell-like chimeric antigen receptor T cells. | Nat Immunol | 2025 | https://conductscience.org/library/papers/39779871 | PubMed |
| 8 | 36416874 | CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. | Cancer Discov | 2023 | https://conductscience.org/library/papers/36416874 | PubMed |
| 9 | 28348046 | B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy. | Clin Cancer Res | 2017 | https://conductscience.org/library/papers/28348046 | PubMed |
| 10 | 31586074 | Genetic modification of primary human B cells to model high-grade lymphoma. | Nat Commun | 2019 | https://conductscience.org/library/papers/31586074 | PubMed |
| 11 | 31270272 | The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. | Sci Transl Med | 2019 | https://conductscience.org/library/papers/31270272 | PubMed |
| 12 | 37192437 | Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/37192437 | PubMed |
| 13 | 26819453 | The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. | Clin Cancer Res | 2016 | https://conductscience.org/library/papers/26819453 | PubMed |
| 14 | 36796019 | Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor. | Blood | 2023 | https://conductscience.org/library/papers/36796019 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BTK | 695 | PubTator's text mining | https://conductscience.org/library/genes/695 | NCBI Gene |
| CD19 | 930 | PubTator's text mining | https://conductscience.org/library/genes/930 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42426348
GET https://conductscience.org/api/papers/v1/42426348/authors